Sanofi’s Chattem Acquires Over-the-Counter Antacid Rolaids®

PR Newswire/Les Echos/ 
PRESS RELEASE 


        Sanofi's Chattem Acqu ires Over-the-Counter Antacid Rolaids(r)
                -- Product acquisition further strengthens 
               Consumer Healthcare Division of Sanofi US --

Paris, France - January 7, 2013 - Sanofi (EURONEXT : SAN and NYSE : SNY) today
announced that its US Consumer Healthcare Division, Chattem, Inc., completed 
the acquisition of the worldwide rights to the Rolaids(r) brand from McNeil 
Consumer Healthcare Division of McNEIL-PPC, Inc.

"The addition of Rolaids represents a rare opportunity to obtain an iconic 
brand that we believe will respond positively to our proven approach of 
growing brands through innovation and advertising," said Zan Guerry, Chief 
Executive Officer, Chattem. "We are primed to leverage the Rolaids market 
opportunity to drive incremental growth and take the brand to a new level."

Rolaids is an over-the-counter antacid that helps relieve heartburn and acid
indigestion. The product was first introduced in 1954 and over the years it 
has been a top selling gastro-intestinal category brand. Chattem will 
re-launch Rolaids and expects the product to be available at retailers within 
a year.

"This acquisition is consistent with our long-term strategy, which includes
growing our consumer healthcare offering as part of a broader diversification
strategy," said Anne Whitaker, President, North America Pharmaceuticals, 
Sanofi. "Chattem has a proven track record of successful acquisitions and 
integrations and the addition of Rolaids, an enduring brand with a deep 
heritage, further diversifies the company's portfolio."

In 2008, Sanofi identified consumer healthcare as a core growth platform for 
the company and subsequently acquired Chattanooga, Tennessee-based Chattem in 
March 2010. The acquisition of Chattem provided Sanofi with a presence in the 
U.S. consumer healthcare market, which represents 25 percent of the current 
worldwide market. In the Spring of 2011, Chattem and Sanofi launched Allegra
over-the-counter (OTC) in what has proven to be one of the most successful 
OTC launches in the U.S.

In addition to Allegra(r), Chattem's portfolio of consumer healthcare brands
includes Icy Hot(r), Gold Bond(r), Cortizone-10(r), Selsun Blue(r), ACT(r) and
Unisom(r).

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, rare diseases, consumer 
healthcare, emerging markets and animal health. Sanofi is listed in Paris 
(EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the 
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking 
statements are statements that are not historical facts. These statements 
include projections and estimates and their underlying assumptions, statements 
regarding plans, objectives, intentions and expectations with respect to 
future financial results, events, operations, services, product development 
and potential, and statements regarding future performance. Forward-looking 
statements are generally identified by the words "expects", "anticipates", 
"believes", "intends", "estimates", "plans" and similar expressions. Although 
Sanofi's management believes that the expectations reflected in such 
forward-looking statements are reasonable, investors are cautioned that 
forward-looking information and statements are subject to various risks and 
uncertainties, many of which are difficult to predict and generally beyond the 
control of Sanofi, that could cause actual results and developments to differ 
materially from those expressed in, or implied or projected by, the 
forward-looking information and statements. These risks and uncertainties 
include among other things, the uncertainties inherent in research and 
development, future clinical data and analysis, including post marketing, 
decisions by regulatory authorities, such as the FDA or the EMA, regarding 
whether and when to approve any drug, device or biological application that 
may be filed for any such product candidates as well as their decisions 
regarding labelling and other matters that could affect the availability or 
commercial potential of such product candidates, the absence of guarantee that 
the product candidates if approved will be commercially successful, the future 
approval and commercial success of therapeutic alternatives, the Group's 
ability to benefit from external growth opportunities, trends in exchange 
rates and prevailing interest rates, the impact of cost containment policies 
and subsequent changes thereto, the average number of shares outstanding as 
well as those discussed or identified in the public filings with the SEC and 
the AMF made by Sanofi, including those listed under "Risk Factors" and 
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual 
report on Form 20-F for the year ended December 31, 2011. Other than as 
required by applicable law, Sanofi does not undertake any obligation to update 
or revise any forward-looking information or statements.

Contacts: 
Sanofi
Media Relations                    Investor Relations
Marisol Péron                      Sébastien Martel
Tél. : + (33) 1 53 77 45 02        Tél. : + (33) 1 53 77 45 45
marisol.peron@sanofi.com           ir@sanofi.com 

Media Relations                    Investor Relations
Jack Cox                           George Grofik
Tel.: 908 981 5280                 Tel.: 908 981 6031
Jack.cox@sanofi.com                George.grofik@sanofi.com


                  
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Jan/07/2013 13:15 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.